IFRX vs. SKYE, SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, and LLY
Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Skye Bioscience (SKYE), Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceutical preparations" industry.
InflaRx (NASDAQ:IFRX) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
InflaRx received 231 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 64.19% of users gave InflaRx an outperform vote.
InflaRx's return on equity of -37.37% beat Skye Bioscience's return on equity.
InflaRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.
42.4% of InflaRx shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 0.7% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, InflaRx and InflaRx both had 2 articles in the media. Skye Bioscience's average media sentiment score of 1.24 beat InflaRx's score of 0.96 indicating that Skye Bioscience is being referred to more favorably in the news media.
Skye Bioscience has lower revenue, but higher earnings than InflaRx.
InflaRx currently has a consensus target price of $13.50, suggesting a potential upside of 844.06%. Skye Bioscience has a consensus target price of $22.00, suggesting a potential upside of 89.49%. Given InflaRx's stronger consensus rating and higher possible upside, research analysts plainly believe InflaRx is more favorable than Skye Bioscience.
Summary
InflaRx beats Skye Bioscience on 9 of the 14 factors compared between the two stocks.
Get InflaRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools